|
|
|
| Effect of Docetaxel Combined with Capecitabine and Oxaliplatin on Serum Levels of Tumor Markers in Patients with Advanced Gastric Cancer |
| ZHANG Nu, WANG Jing, CHEN Zhen-lin, et al |
| Department of Pharmacy, the People's Hospital, Fushun County, Sichuan Province 643200 |
|
|
|
|
Abstract 【Objective】To investigate the effect of docetaxel combined with capecitabine and oxaliplatin on serum levels of tumor markers in patients with advanced gastric cancer. 【Methods】Sixty patients with advanced gastric cancer were analyzed retrospectively. According to different chemotherapy regimens, the patients were divided into FOLFOX group (group A ,calcium folinate +5- fluorouracil + oxaliplatin, n=28) and group DOX (group B,docetaxel + capecitabine + oxaliplatin, n =32). The effects of chemotherapy were compared between the two groups, and changes of serum levels of tumor markers carbohydrate CA125, CEA,TPS,CA199, CYFRA21-1 in the two groups before and after treatment were monitored. The changes of serum levels of IL-2, TNF-α, VEGF and NO were compared between the two groups before and after treatment. 【Results】①The total remission rate of the group B was slightly higher than that of the group A ( P > 0.05). ②Before chemotherapy, there were no statistically significant differences between the two groups in levels of CA125, CEA, TPS, CYFRA21-1, CA199, IL-2, TNF-α, VEGF and NO ( P > 0.05), after treatment, the above indexes were decreased in the two groups ( P < 0.05), and the levels of tumor markers in the group B were lower than those in the group A ( P < 0.05). ③The incidence of side effects in the group B was slightly lower than that in the group A ( P > 0.05). 【Conclusion】The total remission rate of patients with advanced gastric cancer treated by DOX chemotherapy is high and the tolerance of patients is good. Meanwhile, the regimen can decrease the levels of serum tumor markers, inflammation and vascular endothelial factors.
|
|
Received: 24 May 2017
|
|
|
|
|
|
[1] 刘丽英,陈小兵,高明,等.多西他赛联合奥沙利铂卡培他滨治疗晚期胃癌的临床研究[J].中国肿瘤临床,2011,38(8):470-472.
[2] 乌云高娃,李文新,苏日拉,等.多西他赛联合奥沙利铂、卡培他滨一线治疗晚期胃癌临床观察[J].现代肿瘤医学,2014,22(12):2936-2937.
[3] 刘瑾,马韬,叶正宝,等.多西他赛联合奥沙利铂及卡培他滨治疗进展期胃癌的疗效及安全性评估——单中心非对照Ⅱ期临床研究[J].中华胃肠外科杂志,2010,13(3):177-180.
[4] 杨学宁,吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):85-90.
[5] 抗癌药急性及亚急性毒性反应分度标准(WHO标准)[J].癌症,1992,03:254.
[6] 江冠铭,贾筠,林顺欢,等.DOX与DCF方案治疗晚期胃癌的临床研究[J].现代中西医结合杂志,2013,22(21):2332-2333.
[7] 陈建军,肖佩玲.多西他赛联合奥沙利铂与替加氟方案治疗晚期胃癌疗效观察[J].医学临床研究,2015,32(3):519-520,524. |
|
|
|
2018, Vol. 35 
